| Rebecca Blackson, FNP-BC | |
|
3231 Sw 34th Ave, Ocala, FL 34474-8489 | |
| (352) 873-7400 | |
| (354) 873-7464 |
| Full Name | Rebecca Blackson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 3231 Sw 34th Ave, Ocala, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205373750 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | ARNP9312651 (Florida) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | APRN9312651 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Ocala | Ocala, FL | Hospital |
| Marion Communtiy Hospital | Ocala, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Comprehensive Palliative Care L L C | 4082787254 | 8 |
News Archive
Optibrium, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
Treating polycystic ovary syndrome as only a fertility condition is leaving those with the condition at greater risk of developing related long-term health conditions, according to women surveyed and interviewed in University of Warwick research.
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.
President Joe Biden's edict that nursing homes must ensure their workers are vaccinated against covid-19 presents a challenge for an industry struggling to entice its lowest-paid workers to get shots without driving them to seek employment elsewhere.
GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.
› Verified 4 days ago
| Entity Name | Florida Cancer Specialists & Research Institute, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760590962 PECOS PAC ID: 2567356058 Enrollment ID: O20040216000091 |
News Archive
Optibrium, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
Treating polycystic ovary syndrome as only a fertility condition is leaving those with the condition at greater risk of developing related long-term health conditions, according to women surveyed and interviewed in University of Warwick research.
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.
President Joe Biden's edict that nursing homes must ensure their workers are vaccinated against covid-19 presents a challenge for an industry struggling to entice its lowest-paid workers to get shots without driving them to seek employment elsewhere.
GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.
› Verified 4 days ago
| Entity Name | Ocala Heart Clinic Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649442906 PECOS PAC ID: 4880772615 Enrollment ID: O20080421000148 |
News Archive
Optibrium, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
Treating polycystic ovary syndrome as only a fertility condition is leaving those with the condition at greater risk of developing related long-term health conditions, according to women surveyed and interviewed in University of Warwick research.
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.
President Joe Biden's edict that nursing homes must ensure their workers are vaccinated against covid-19 presents a challenge for an industry struggling to entice its lowest-paid workers to get shots without driving them to seek employment elsewhere.
GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.
› Verified 4 days ago
| Entity Name | Center For Comprehensive Palliative Care L L C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871791574 PECOS PAC ID: 4082787254 Enrollment ID: O20080721000764 |
News Archive
Optibrium, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
Treating polycystic ovary syndrome as only a fertility condition is leaving those with the condition at greater risk of developing related long-term health conditions, according to women surveyed and interviewed in University of Warwick research.
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.
President Joe Biden's edict that nursing homes must ensure their workers are vaccinated against covid-19 presents a challenge for an industry struggling to entice its lowest-paid workers to get shots without driving them to seek employment elsewhere.
GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rebecca Blackson, FNP-BC 3231 Sw 34th Ave, Ocala, FL 34474-8489 Ph: (352) 873-7400 | Rebecca Blackson, FNP-BC 3231 Sw 34th Ave, Ocala, FL 34474-8489 Ph: (352) 873-7400 |
News Archive
Optibrium, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
Treating polycystic ovary syndrome as only a fertility condition is leaving those with the condition at greater risk of developing related long-term health conditions, according to women surveyed and interviewed in University of Warwick research.
One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.
President Joe Biden's edict that nursing homes must ensure their workers are vaccinated against covid-19 presents a challenge for an industry struggling to entice its lowest-paid workers to get shots without driving them to seek employment elsewhere.
GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.
› Verified 4 days ago